About
Contact
Subscribe
e-Edition

Make Home Page

Dashboard
Logout

- My Account
- Dashboard
- Profile
- Saved items
- Logout

Facebook
Twitter

- Site search

Home
News
Sports
- Local Sports
- National Sports
Business
Opinion
A & E
Life
Features & Magazines
Classifieds
Weather
Obituaries
Parcel Pickup

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

State Street SPDR S&P Biotech ETF (NY:XBI)

123.22 -3.52 (-2.78%)

Streaming Delayed Price Updated: 10:18 AM EST, Feb 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about State Street SPDR S&P Biotech ETF

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

15 16 Next >

Why These 3 Nasdaq Stocks Buckled Today ↗

May 16, 2023

The FTC's decision to sue to block a high-profile merger is weighing on biotech valuations today.

Via The Motley Fool

Time To Play Small Cap Life Science Stocks ↗

May 15, 2023

The overall market sentiment has been hit hard by MACRO concerns. The dominating narrative is the Fed and the Debt Ceiling.

Via Talk Markets

Biotech ETFs Pop On M&A Resurgence ↗

May 10, 2023

The biopharma industry has seen a recent upswing in mergers and acquisitions (M&A).

Via Talk Markets

Something Happened In Biotech Last Week ↗

May 08, 2023

Biotech stocks were more constructive last week with some sharp moves up.

Via Talk Markets

Small & Mid Cap Life Science Stock Portfolio: Some Good Picks In A Stalled Sector ↗

May 01, 2023

A pivotal week looks to be shaping up with the usual macro concerns arising, such as a Fed meeting and big earnings waiting just around the corner. One possible path to help navigate around these macro...

Via Talk Markets

Second Quarter Outlook For Biotech Stocks ↗

April 25, 2023

Biotech stocks have been consolidating recently but may be ready to rally higher due to factors such as a declining 10-year yield and growing M&A activity.

Via Talk Markets

“Knockin’ On Heaven’s Door” Stock Market (And Sentiment Results) ↗

April 20, 2023

We’ve come through the “point of control” on the S&P 500. This simply means there is less “overhead supply” to come on the market as we press higher.

Via Talk Markets

Where Is The Current Bull Market? Scan Of Stocks Gaining Over 20% Over The Past Week Almost Exclusively Yields Biotech Names ↗

April 20, 2023

Where is the current bull market? All indications would be that it's in biotech! The broader market is not really moving. There have been plenty of attention-grabbing headlines, and earnings season is...

Via Benzinga

Thermo Fisher, Principal Financial Group, And Two Promising ETFs Steal The Show On CNBC's 'Final Trades' ↗

April 14, 2023

On CNBC’s "Halftime Report Final Trades," Bryn Talkington of Requisite Capital Management named SPDR S&P Biotech ETF (NYSE: XBI), which is trading in a tight range <

Via Benzinga

Mifepristone Abortion Pill Access in Limbo: Justice Department May Ask Supreme Court's Intervention ↗

April 13, 2023

U.S. Attorney General Merrick Garland said that the Justice Department would file an appeal with the U.S. Supreme Court seeking to block the entirety of Kacsmaryk's order suspending the FDA approval of...

Via Benzinga

Women's Reproductive Rights: US Court Preserves Access To Abortion Pill For Now, But With Tighter Rules ↗

April 13, 2023

A U.S. federal appeals court has temporarily blocked a decision by a Texas judge to halt the FDA's approval of a widely used abortion drug.

Via Benzinga

New York and California Prepare For Potential Mifepristone Ban In Texas With Stockpiling Of Alternative Abortion Medications ↗

April 12, 2023

New York and California are stockpiling an alternative abortion medication in case a Texas judge's order suspending the FDA approval of the primary drug, mifepristone, goes into effect later this...

Via Benzinga

Attorney Generals of Over 20 States Sound Alarm Over Suspension Of Abortion Med Approval: "Devastating Risks" Ahead ↗

April 11, 2023

In a new court filing, the Democratic attorneys general for 23 U.S. states have reportedly warned that a federal judge's decision to suspend the FDA's approval of mifepristone "presents devastating...

Via Benzinga

Time to Spring-Clean...Your Stock Portfolio ↗

April 10, 2023

Plus, Howard Marks, co-founder of Oaktree Capital Management, joins the podcast to discuss topics including China's effect on inflation in the U.S.

Via The Motley Fool

April Is Busting Out For Healthcare And Biotech ↗

April 10, 2023

Last week was a good week for healthcare stocks and most large cap biopharmaceutical stocks resumed an upward trend.

Via Talk Markets

FDA Withdraws Lone Premature Birth Drug Makena Over Lack of Proven Benefits ↗

April 06, 2023

Via Benzinga

Large Cap Biopharmaceuticals Q1 2023: In This Bullish Run Biotech Lags ↗

April 03, 2023

It was very difficult to make money in Q1 trading healthcare or biotech ETFs because of the sharp rally in other sectors. Nonetheless, there were two big winners.

Via Talk Markets

The Stock Market Rally May Fizzle The Week Of April 3 ↗

April 02, 2023

I think what we’ve seen over the last week or two has been driven by systematic trading and rebalancing of portfolios, as investors have sold financials and moved into mega-cap technology names. But...

Via Talk Markets

Biotech And Life Science Trades: Q1 2023 Performance By The Numbers ↗

April 01, 2023

Despite a strong month and a great finish to the quarter, many traders remain cautious about the market. It’s been a volatile time after the collapse of Silicon Valley Bank, but the first quarter of...

Via Talk Markets

“Don’t Stop Believin'” Stock Market (And Sentiment Results) ↗

March 30, 2023

In this week’s AAII Sentiment Survey result, bullish percent ticked up to 22.5% from 20.9% the previous week.

Via Talk Markets

This Blue Chip Dividend Stock Should Return to Form When the Risk Premium Flips ↗

March 30, 2023

T-bills may be the flavor of the month, but history has shown this top biotech stock is a far better long-term investment.

Via The Motley Fool

The 3 Best Growth Stocks to Buy in the Biotech Sector ↗

March 29, 2023

These three biotech growth stocks are brimming with potential and could offer massive upside for patient investors.

Via InvestorPlace

Can Healthcare Stocks Survive Macro Headwinds? ↗

March 27, 2023

Healthcare stocks are supposed to be defensive plays in a choppy market. However, over the past 18 months, the XLV is flat and down 6% over one year.

Via Talk Markets

US Judge Weighs Nationwide Ban On Abortion Pills ↗

March 16, 2023

U.S. District Judge Matthew Kacsmaryk questioned President Joe Biden's administration lawyers on whether the federal regulatory approval of the abortion pill mifepristone was proper. The judge is...

Via Benzinga

The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector ↗

March 15, 2023

To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy.

Via InvestorPlace

Biotech Stocks And The SVB Collapse — Here's What We Know ↗

March 14, 2023

The collapse of SVB will have a big impact on early-stage, venture-backed companies.

Via Investor's Business Daily

Silicon Valley Bank Meltdown Hits Healthcare Sector As Well ↗

March 13, 2023

The Federal Deposit Insurance Corporation (FDIC) closed Silicon Valley Bank, the banking arm of SVB Financial Group (NASDAQ:

Via Benzinga

Small Cap Biotechs Slammed By SVB Collapse ↗

March 13, 2023

Nothing like a banking crisis to start off a weekend. But maybe by the end of this upcoming week of turmoil we'll worry less about inflation.

Via Talk Markets

6 Stock Market Thoughts For The Week Of March 13 ↗

March 12, 2023

A flight to safety seemed to be at play this week, with the market seeking safety first and asking questions later. This is not unusual, and once the situation is resolved, much of the decline in rates...

Via Talk Markets

Hefty Listing Price Of New Drugs For Cancer, Rare Diseases Put Pressure On Annual Hike For Older Drugs ↗

March 10, 2023

New branded medicines are coming to market with ever-higher price tags as soon as the first day. Amgen Inc's (NASDAQ: AMGN) lung cancer treatment, Lumakras, carried a hefty price tag of $17,900 per...

Via Benzinga

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

15 16 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sections

News
Sports
Opinion
Photo Galleries
Videos
Local Events
Classifieds
Obituaries

Services

About
Contact
Personnel
Advertise
Subscription Services
Promote Your Event
Dealer Locations
Email Alerts
Submission Forms

Contact Information

chroniclejournal.com
75 S. Cumberland Street
Thunder Bay, ON P7B 1A3
Phone: 807 343 6200
Email: circulation@chroniclejournal.com

Facebook
Twitter

Browser Compatibility

Your browser is out of date and potentially vulnerable to security risks.
We recommend switching to one of the following browsers:

Microsoft Edge Google Chrome Firefox

State Street SPDR S&P Biotech ETF (NY:XBI)

Headline News about State Street SPDR S&P Biotech ETF

Sections

Services

Contact Information

Follow Us